Skip to main content
Pyxis Oncology, Inc. logo

Pyxis Oncology, Inc. — Investor Relations & Filings

Ticker · PYXS ISIN · US7473241013 US Manufacturing
Open in API
Filings indexed 308 across all filing types
Latest filing 2022-07-01 Regulatory Filings
Country US United States of America
Listing US PYXS

About Pyxis Oncology, Inc.

https://pyxisoncology.com/

Pyxis Oncology, Inc. is a clinical-stage company focused on developing next-generation therapeutics for difficult-to-treat cancers. The company's differentiated portfolio of clinical assets is centered on two primary modalities: antibody-drug conjugates (ADCs) and immuno-oncology (IO). Its ADC technology platform is designed to deliver potent cancer-killing agents directly to tumor cells for enhanced safety and efficacy. The immuno-oncology programs utilize monoclonal antibodies (mAbs) to mobilize the body's immune system to attack cancer cells by blocking tumor defense mechanisms and overcoming immune suppression. Pyxis Oncology is advancing its product candidates as both monotherapies and in combination with other therapies to improve outcomes for patients with solid tumors.

Recent filings

Filing Released Lang Actions
S-8
Regulatory Filings Classification · 100% confidence The document is a Form S-8 Registration Statement filed with the SEC by Pyxis Oncology, Inc. Form S-8 is used for registering securities to be offered under employee benefit plans, such as inducement plans. The text includes detailed legal and corporate governance information related to indemnification of directors and officers, incorporation of documents by reference, and exhibits related to the registration statement. It is not a financial report, earnings release, or management discussion. It is a regulatory filing related to securities registration under the Securities Act of 1933. Therefore, it fits best under the category of Regulatory Filings (RNS), which is the fallback for miscellaneous SEC filings that do not fit other categories.
2022-07-01 English
8-K
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated June 13, 2022, reporting on the Annual Meeting of Stockholders of Pyxis Oncology, Inc. It details the submission of matters to a vote of security holders, including election of a director and ratification of the independent auditor. The key content is the official results of shareholder votes at the Annual Meeting. The document length is 3908 characters, which is relatively short and focused solely on voting results. This matches the definition of 'Declaration of Voting Results & Voting Rights Announcements' (DVA). It is not an Annual Report, Audit Report, or Management Report, nor is it a Proxy Solicitation or Presentation. Therefore, the correct classification is DVA with high confidence.
2022-06-14 English
SC 13D/A
Major Shareholding Notification
2022-05-23 English
10-Q
Interim / Quarterly Report Q1 2022
2022-05-13 English
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events. The text specifically mentions Item 2.02 "Results of Operations and Financial Condition" and states that the company issued a press release announcing its financial results for the quarter ended March 31, 2022. The document includes a press release as an exhibit but does not contain the full financial statements or detailed financial analysis itself. The length is 3490 characters, which is relatively short and consistent with a current report filing rather than a full quarterly or annual report. The document is primarily an announcement of financial results via a press release, not the full earnings release or interim report itself. Therefore, the best classification is Earnings Release (ER), as it corresponds to the initial announcement of quarterly financial results (key highlights only).
2022-05-13 English
DEFA14A
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a Schedule 14A filing, which is a proxy statement or related materials filed with the SEC. It includes information about the Annual Meeting of Stockholders, voting instructions, and proposals to be voted on, such as election of directors and ratification of auditors. The document is titled 'Definitive Additional Materials' related to the proxy statement and does not contain the full proxy statement itself but rather additional materials or notices related to the proxy. The document length is 3805 characters, which is relatively short and consistent with a notice or additional proxy materials rather than a full proxy statement. According to the filing definitions, proxy solicitation and information statements are classified under code PSI. Therefore, this document is best classified as Proxy Solicitation & Information Statement (PSI).
2022-04-28 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.